On the other hand, tumor mutational burden (TMB) has been significantly associated with greater benefit from ICIs in terms of ORR, PFS, and OS; a benefit that is even greater if associated with PD-L1 expression [80,81,82,83]. Here, CD274 is linked to neoplasm.